STF Management LP Has $1.36 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

STF Management LP decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 19,818 shares of the biopharmaceutical company’s stock after selling 941 shares during the period. STF Management LP’s holdings in Gilead Sciences were worth $1,360,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Renaissance Technologies LLC increased its holdings in Gilead Sciences by 17.1% in the second quarter. Renaissance Technologies LLC now owns 5,057,598 shares of the biopharmaceutical company’s stock valued at $347,002,000 after purchasing an additional 739,948 shares during the last quarter. Citizens Financial Group Inc. RI grew its position in shares of Gilead Sciences by 36.1% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 5,984 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 1,588 shares during the period. One Capital Management LLC increased its stake in shares of Gilead Sciences by 36.8% in the 2nd quarter. One Capital Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 1,560 shares during the last quarter. Sierra Summit Advisors LLC acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $783,000. Finally, Dimensional Fund Advisors LP boosted its stake in Gilead Sciences by 2.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company’s stock worth $714,421,000 after acquiring an additional 268,208 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,847 shares of company stock worth $3,002,940. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on GILD. BMO Capital Markets upped their target price on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Truist Financial upped their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Royal Bank of Canada lifted their target price on Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a report on Wednesday, September 4th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Twelve investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.06.

Gilead Sciences Stock Down 0.4 %

Shares of GILD stock opened at $82.81 on Monday. The firm’s fifty day moving average price is $75.48 and its two-hundred day moving average price is $70.84. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The firm has a market capitalization of $103.10 billion, a P/E ratio of 230.03, a PEG ratio of 2.80 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. On average, equities analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.72%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.